局限性默克尔细胞癌原发肿瘤部位驱动不同管理策略但不影响肿瘤学结局
本研究纳入2014-2021年在本机构接受辅助放疗的80例临床I-II期默克尔细胞癌患者,比较头颈部与非头颈部原发部位的管理模式和结局。头颈部肿瘤较少行广泛局部切除、较少行前哨淋巴结活检、更多接受选择性淋巴结放疗且辅助放疗剂量更高,但两组的3年局部、淋巴结和总无复发生存均无显著差异。
要点
- 头颈部原发肿瘤较少行广泛局部切除(81% vs 100%,p<0.01)。
- 头颈部肿瘤更多接受选择性淋巴结放疗(48% vs 0%)且辅助放疗剂量>50 Gy比例更高(70% vs 8%)。
- 尽管管理策略不同,两组3年局部、淋巴结和总无复发生存均无显著差异。
核心结论
- 在初始治疗包含放疗的原发性默克尔细胞癌患者中,解剖部位驱动的异质性治疗策略与同样优秀的局部区域疾病控制相关。
研究设计与样本
- 本研究为在本机构接受治疗的临床I-II期默克尔细胞癌患者的队列研究,纳入2014-2021年间接受原发部位和/或区域淋巴结辅助放疗作为根治性治疗组成部分的患者80例。
主要发现
- 头颈部原发42例(53%),非头颈部原发38例(47%)。
- 头颈部肿瘤患者行广泛局部切除的比例较低(头颈部81% vs 非头颈部100%,p<0.01)。
- 在行广泛局部切除的患者中,头颈部肿瘤患者接受>50 Gy辅助放疗的比例较高(头颈部70% vs 非头颈部8%,p<0.01)。
- 头颈部肿瘤患者行前哨淋巴结活检的比例较低(头颈部62% vs 非头颈部100%,p<0.01),接受选择性淋巴结放疗的比例较高(头颈部48% vs 非头颈部0%)。
- 两组3年局部无复发生存(头颈部94% vs 非头颈部94%,p=0.97)、淋巴结无复发生存(头颈部89% vs 非头颈部85%,p=0.71)和总无复发生存(头颈部73% vs 非头颈部80%,p=0.44)均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Clinically localized Merkel cell carcinoma (MCC) has been associated with high rates of disease relapse. This study examines how primary tumor anatomic site drives patterns of care and outcomes in a large cohort treated in the contemporary era. MATERIALS AND METHODS: Patterns of care and associated outcomes were evaluated for clinically Stage I-II MCC patients treated at our institution with adjuvant radiation therapy (RT) to the primary site and/or regional nodal basin as a component of their curative intent therapy between 2014-2021. RESULTS: Of 80 patients who met inclusion criteria, the primary tumor anatomic site was head and neck (HN) for 42 (53%) and non-head and neck (NHN) for 38 (47%). Primary tumor risk factors were similar between cohorts. Fewer patients with HN tumors had wide local excision (WLE; HN-81% vs. NHN-100% p < 0.01). Of those undergoing WLE, patients with HN tumors received higher dose adjuvant RT (>50 Gy: HN-70% vs. NHN-8%; p < 0.01). Patients with HN tumors were less likely to undergo sentinel lymph node biopsy (HN-62%vs. NHN-100%; p < 0.01) and more likely to have elective nodal RT (HN-48% vs. NHN-0%). Despite varying management strategies, there was no significant difference in local recurrence-free survival (3-yr LRFS HN-94% vs. NHN-94%; p = 0.97), nodal recurrence-free survival (3-yr NRFS HN-89% vs. NHN-85%; p = 0.71) or overall recurrence-free survival (3-yr RFS 73% HN vs. 80% NHN; p = 0.44). CONCLUSIONS: Among patients with primary MCC who had RT as a component of their initial treatment strategy, anatomically-driven heterogeneous treatment approaches were associated with equally excellent locoregional disease control.
引用
- Cass S, Cope B, Bishop AJ, et al. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol. 2023. PMID: 37659660. doi:10.1016/j.radonc.2023.109892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。